The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...

L’Oreal OR0.54%increase; green up pointing triangle will sell part of its stake in Sanofi SAN 0.43%increase; green up pointing triangle back to the French pharmaceutical company for 3 billion ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

According to Sanofi, tolebrutinib is the first investigational BTK inhibitor with the ability to reach the brain… A PhD student at the UMass Chan Medical School will use funding from a newly ...

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript ... we're pleased with the positive Phase 3 results of fitusiran, rilzabrutinib, and tolebrutinib. They provide the foundation for potential ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...

Tolebrutinib has been submitted in line with ... This is a demonstration of Sanofi's commitment, unwavering commitment to patients with MS. Thanks very much. I'll just, go simple and try to ...

As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call ...

Sanofi also has a strong immunology and neuro-inflammation pipeline, which includes some potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

The French drugmaker added the BTK inhibitor tolebrutinib to its pipeline by acquiring Principia for $3.7 billion. Facing down skepticism, Sanofi guided the asset to mixed phase 3 data last year ...